Biotech & MedTech News
-
FendX Completes Second Pilot Run to Manufacture REPELWRAP(TM) Film Using Dunmore’s Commercial Equipment
January 10, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
January 9, 2024 (Source) — Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences…
-
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
January 4, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Hemostemix Clarifies its October 3, 2023 News Release
December 29, 2023 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
FendX Technologies Announces Non-Brokered Private Placement with Strategic Investors
December 20, 2023 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
Zentek Launches Triera Biosciences Ltd.
December 13, 2023 (Source) – Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization…
-
FendX Signs Collaborative Research Agreement with McMaster for Development of Catheter Coating Using Its Nanotechnology
December 13, 2023 (Source) – FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a…
-
DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
December 11, 2023 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Zentek and 1Click Heating and Cooling Sign Distribution Agreement
December 8, 2023 (Source) — Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company…
-
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated to Complete Patient Recruitment during Q1…
